

# PRECEPTORSHIP PROGRAMME

## Metastatic Bladder and Kidney Cancer

**ESMO  
PRECEPTORSHIP**

**LUGANO SWITZERLAND  
27-28 MARCH 2023**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

**Co-Chairs**

Thomas Powles, United Kingdom  
Cristina Suárez, Spain

# ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

Lugano, Switzerland  
27-28 March 2023

---

## CO-CHAIRS

Thomas Powles, United Kingdom  
Cristina Suárez, Spain

## SPEAKERS

Axel Bex, Netherlands  
Viktor Grünwald, Germany  
Friederike Schlürmann, France  
Bernadett Szabados, United Kingdom  
Michiel van der Heijden, Netherlands  
Ursula Vogl, Switzerland

---

## LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

---

## ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by the following partners



Supported by an **independent educational grant** from **Pfizer Inc.** and the **Healthcare business of Merck KGaA**, Darmstadt, Germany

---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Monday, 27 March 2023

<b>09:00-09:15</b> 15'	<b>Opening and welcome</b>	
15'	Welcome from ESMO - Objectives and scientific introduction	Thomas Powles, UK Cristina Suárez, ES
<b>09:15-10:30</b> 75'	<b>SESSION 1</b> <b>Bladder Cancer – Part I</b>	<b>Co-Chairs:</b> <b>Thomas Powles, UK</b> <b>Cristina Suárez, ES</b>
30'	Localized and systemic standard treatments in non-muscle-invasive bladder cancer <ul style="list-style-type: none"> <li>- Localized treatment</li> <li>- Surgery</li> </ul>	Bernadett Szabados, UK Axel Bex, NL
15'	Approaches to upper tract UC	Axel Bex, NL
15'	New treatments and approaches to NMIBC	Bernadett Szabados, UK
15'	Discussion	Faculty
<b>10:30-11:00</b>	<b>Coffee break</b>	
<b>11:00-12:45</b> 105'	<b>SESSION 2</b> <b>Bladder Cancer – Part II</b>	<b>Co-Chairs:</b> <b>Axel Bex, NL</b> <b>Ursula Vogl, CH</b>
20'	Debate: Adjuvant chemotherapy or immune therapy for MIBC <ul style="list-style-type: none"> <li>- Adjuvant chemotherapy</li> <li>- Immune therapy</li> </ul>	Thomas Powles, UK Michiel van der Heijden, NL
15'	Established and novel neoadjuvant treatments for MIBC	Michiel van der Heijden, NL
15'	First line treatment in advanced bladder cancer	Thomas Powles, UK
15'	Sequencing therapy in advanced bladder cancer	Friederike Schlürmann, FR
10'	Discussion	Faculty
30'	Participants clinical case discussion (3x10')	Faculty
<b>12:45-13:45</b>	<b>Lunch</b>	
<b>13:45-15:25</b> 100'	<b>SESSION 3</b> <b>Renal Cancer – Part I</b>	<b>Co-Chairs:</b> <b>Viktor Grünwald, DE</b> <b>Cristina Suárez, ES</b>
10'	Surgery and other techniques for primary tumour	Axel Bex, NL
15'	Is there a role for nephrectomy in advanced disease?	Ursula Vogl, CH
10'	The role of metastasectomy and SBRT in RCC	Friederike Schlürmann, FR
15'	Neoadjuvant and adjuvant treatment in RCC	Cristina Suárez, ES
10'	Discussion	Faculty
40'	Participants clinical case discussion (4x10')	Faculty
<b>15:25-15:55</b>	<b>Coffee Break</b>	

<b>15:55-17:10</b> 75'	<b>SESSION 4</b> <b>Renal Cancer – Part II</b>	<b>Co-Chairs:</b> <b>Thomas Powles, UK</b> <b>Bernadett Szabados, UK</b>
20'	Debate: Immune combinations or VEGF/PD1 inhibition as 1st line therapy for advanced clear cell RCC - Immune combinations - VEGF/PD1 inhibition	Ursula Vogl, CH Viktor Grünwald, DE
20'	Second line and beyond	Cristina Suárez, ES
20'	Biology and treatment of non-clear RCC	Viktor Grünwald, DE
15'	Discussion	Faculty

<b>19:00</b>	<b>Dinner</b>
--------------	---------------

## Tuesday, 28 March 2023

<b>09:00-10:30</b> 90'	<b>SESSION 5</b> <b>Bladder and RCC biology of disease</b>	<b>Co-Chairs:</b> <b>Friederike Schlürmann, FR</b> <b>Michiel van der Heijden, NL</b>
15'	Biomarkers beyond PD-L1 in bladder cancer	Thomas Powles, UK
15'	Circulating biomarkers in bladder and kidney cancer	Bernadett Szabados, UK
15'	Personalised therapy in RCC: Fact or fiction	Viktor Grünwald, DE
15'	New drugs in bladder cancer beyond ADCs	Michiel van der Heijden, NL
15'	New drugs in RCC: Targeted, immune and cellular therapies	Cristina Suárez, ES
15'	Discussion	Faculty

<b>10:30-11:00</b>	<b>Coffee break</b>
--------------------	---------------------

<b>11:00-12:45</b> 105'	<b>SESSION 6</b> <b>Focus on toxicity and duration of therapy</b>	<b>Co-Chairs:</b> <b>Viktor Grünwald, DE</b> <b>Cristina Suárez, ES</b>
15'	Can we stop targeted therapy, immune or ADC therapy?	Friederike Schlürmann, FR
15'	Optimising CTLA-4 in renal and bladder cancer	Ursula Vogl, CH
15'	ADCs present and future in bladder cancer	Michiel van der Heijden, NL
15'	Treatment after progression on adjuvant therapy in renal and bladder cancer	Axel Bex, NL
15'	Discussion	Faculty
30'	Participants clinical case discussion (3x10')	Faculty

<b>12:45-12:55</b> 10'	<b>Conclusion and farewell</b>	<b>Cristina Suárez, ES</b>
---------------------------	--------------------------------	----------------------------

<b>12:55-13:55</b>	<b>Lunch</b>
--------------------	--------------

**Note:** Each 10 minute slot for participant clinical case discussion includes a 5' case presentation and a 5' Q&A / discussion